DJS Law Group says Regeneron faces class action over Fianlimab-Libtayo trial claims
DJS Law Group says investors can contact the firm about a class action against Regeneron Pharmaceuticals over claims tied to its Phase III Fianlimab-Libtayo study.
DJS Law Group says investors can contact the firm about a class action against Regeneron Pharmaceuticals over claims tied to its Phase III Fianlimab-Libtayo study.
DJS Law Group said in a PR Newswire release on Aug. 21, 2026, that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc., the Nasdaq-listed drugmaker known by the ticker REGN. The release says the suit concerns alleged securities law violations tied to statements about the company’s Phase III Fianlimab-Libtayo study.
The notice says the case alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. It also says the proposed class period runs from Aug. 1, 2025, to May 15, 2026.
According to the release, the complaint says Regeneron made false and misleading statements to the market, gave investors the impression that the Phase III study showed signs of success, and minimized risks connected to the trial. The release says the study later failed to achieve its primary endpoint in a statistically significant manner.
The PR Newswire item does not say whether Regeneron has responded to the allegations in the lawsuit.
The release provides no additional background on the trial results or on any court rulings. It says shareholders who purchased REGN shares during the class period may contact the firm about possible lead plaintiff appointments. It also says lead plaintiff status is not required to share in any recovery.
What happens next depends on the litigation process, including whether investors seek lead plaintiff status and how the case proceeds in court, according to the notice.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.